Top 10 CRISPR Stocks to Buy Now

Page 3 of 10

8. Pacific Biosciences of California, Inc. (NASDAQ:PACB)

Number of Hedge Fund Holders: 14

Pacific Biosciences of California (NASDAQ:PACB) ranks among the best CRISPR stocks to buy. Speaking on its strategic developments and challenges, Pacific Biosciences of California (NASDAQ:PACB) delivered a presentation at the 46th Annual Global Healthcare Conference hosted by Goldman Sachs on June 11. The company discussed its financial performance, highlighting both market limitations and growth prospects, and emphasized the promise of its long-read sequencing technology.

Financially speaking, Pacific Biosciences of California (NASDAQ:PACB) reported that its consumable revenue in Q1 2025 reached a record $20.1 million, a 26% increase from the previous year. Additionally, by improving its gross margin, cutting operational costs, and increasing top-line growth, the company targets profitability by 2027.

Pacific Biosciences of California (NASDAQ:PACB) is a biotech company that focuses on advanced genomic technologies, such as whole-genome sequencing, target sequencing, RNA sequencing, and epigenetics. By using its PacBio Sequel System, the company also developed a novel enrichment method for targeted SMRT sequencing. This greatly improves sequencing efficiency by using the CRISPR-Cas9 system to do away with the necessity for PCR amplification.

Page 3 of 10